Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy.
Hepatitis E virus (HEV) infection is one of the most common causes of acute hepatitis worldwide. HEV genotype 3 infections can become chronic in immunocompromised patients, defined as HEV RNA persisting in the blood for more than 3 months after an infection [1] . Solid-organ transplant recipients, patients with hematological disorders, and those infected with human immunodeficiency virus (HIV) can all develop chronic hepatitis and cirrhosis [2] . The chronic HEV infections of transplant patients may be resolved by decreasing immunosuppression; this leads to spontaneous clearance in about 30% of them [3] . When this is unsuccessful, ribavirin, a guanosine analogue, seems to be the best treatment for patients with several types of transplant [2] . A recent multicenter study found a sustained virological response (SVR) in 46 of the 59 patients (78%) given ribavirin as monotherapy for a mean duration of 3 months [4] . The SVR rate increased to 85% when 4 relapsers were retreated for a longer period [4] . Little is known about the dynamics of HEV in the stools of patients with chronic infection on ribavirin therapy [5] . We therefore analysed the kinetics of HEV RNA in the stools of 24 solid organ-transplant recipients given ribavirin for 3 months and assessed the relationship between long-term HEV excretion in the stools and the risk of treatment relapse.
PATIENTS AND METHODS

Patients
We studied 24 solid organ-transplant recipients infected chronically with HEV genotype 3 (16 kidney transplants, 5 liver transplants, 2 heart transplants, and 1 lung transplant). We have included all the patients followed in our center that were treated for 3 months with ribavirin and for whom stools and blood samples were available. Initial ribavirin doses were adjusted on the basis of the estimated glomerular filtration rate, as described elsewhere [6] . Samples of feces and blood were collected and tested for HEV RNA before starting treatment (time 0) and at months 1 and 3 (end of treatment). The study was approved by the institutional review boards at Toulouse University hospital. SVR was defined as negative plasma HEV RNA during treatment and 6 months after treatment withdrawal. Relapsers were defined as patients who achieved an end-oftreatment response (undetectable plasma HEV RNA) but in whom HEV RNA reappeared 1 to 3 months after treatment withdrawal.
Virological Parameters
HEV RNA was detected and quantified in the blood and stools using an accredited (ISO 15189) reverse-transcription polymerase chain reaction (RT-PCR) test for HEV [7] . Stool samples were suspended in 5 mL of Minimum Essential Eagle's Medium (MEM, Sigma-Aldricht, France), vortexed, frozen at −20°C for 24 hours, and then centrifuged at 3000 rpm for 10 minutes. The resulting supernatants were passed through a 45 µm filter and the filtrate used for HEV RT-PCR.
Statistical Analyses
Proportions were compared using the χ 2 test or Fisher exact test.
Quantitative variables were compared with the nonparametric Mann-Whitney U-test. P values <.05 were taken to indicate statistical significance.
RESULTS
The ribavirin dose of each or our 24 solid organ transplant patients depended on their kidney function (200-800 mg per day). Their immunosuppressive medication was not modified before or during therapy. After treatment, 15 patients had an SVR (62.5%), and 9 suffered a relapse ( Table 1 ). The studied parameters of the SVR and relapsed patients were not significantly different before treatment. Their plasma HEV RNA concentrations and ribavirin doses were also similar and HEV RNA was detected in the stools of both groups before treatment initiation. The HEV RNA concentrations in plasma and the stools declined during treatment. After 1 month of ribavirin therapy, both plasma and stools of 14 patients (7 SVR and 7 relapsed patients) still contained HEV RNA. The 10 patients with an undetectable plasma virus load included 4 (2 SVR and 2 relapsed) whose stools were HEV RNA-positive; the stools of the other 6 patients were negative. We detected HEV RNA more frequently in the stools of patients who relapsed (100%) than in those who achieved SVR (60%; P = .05).
The plasmas of all 24 patients tested negative for HEV RNA at the end of the 3-month ribavirin treatment. A decreased hemoglobin concentration was the main adverse effect ( Table 1) . The stools of the 15 patients who achieved SVR were all HEV RNA negative. In contrast, we detected HEV RNA in the stools of 6 patients, all of whom suffered a relapse. The stools of only 3 relapsed patients tested negative for HEV RNA at the end of treatment. However, the plasma-ribavirin concentrations, measured 2 months after ribavirin initiation, in both groups of patients were similar (Table 1) . Thus, the frequencies of HEV RNA Positive plasma HEV RNA 3 mo after ribavirin initiation 0 0 .32
Positive stools HEV RNA detection 3 mo after ribavirin initiation 0 6 <.01
Data are presented as median with range.
Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; HEV, hepatitis E virus; SVR, sustained virological response. a Patients with undetectable HEV RNA were estimated to 2 log copies/mL for the median determination.
detection in the stools of patients with SVR (0%) and of those who suffered a relapse (66.6%; P < .001) were significantly different.
DISCUSSION
The results of this study of HEV shedding into the faeces of 24 solid-organ-transplant recipients treated with ribavirin for a chronic hepatitis E infection highlight the importance of such HEV excretion as an indicator of treatment failure. A recent study found that 74% of patients treated with ribavirin for ≤3 months achieved SVR, as did 85% of those given ribavirin for >3 months [4] . Much less is known presently about the dynamics of HEV shedding into stools than of the dynamics of the virus in the plasma of solid organ recipients with a chronic HEV infection given antiviral therapy. Our findings show that HEV is shed into the faeces for longer than HEV viremia persists in these patients. Ambrosioni et al [5] reported recently the case of a woman with chronic lymphocytic leukaemia treated for a chronic HEV infection with 400 mg BID of ribavirin for >48 weeks. Her HEV viremia was undetectable after 6 months of treatment, but her stools remained HEV RNA positive throughout the 48 weeks of treatment. Ribavirin therapy was continued, but there was no indication that she had suffered a relapse after treatment interruption [5] . This prolonged fecal shedding under therapy agrees well with the natural course of untreated HEV infections [8] . The prolonged fecal shedding of HEV by patients on ribavirin therapy is consistently associated with a relapse. Another study found that none of the 11 solid organ-transplant-recipients treated for 5 months suffered a relapse [9] , suggesting that these patients could benefit from extending the treatment to completely clear HEV RNA from both the blood and stools. Alternatively, a higher dose could be used, but data supporting this strategy are lacking.
All the stool samples from the 15 of our patients who achieved SVR were HEV RNA negative 6 months after treatment withdrawal, indicating that the ribavirin therapy cleared the virus from both plasma and feces. Our data for patients who suffered a relapse suggest that their ribavirin dose was high enough to inhibit replication in the liver but not in the gastrointestinal tract. Animal models of HEV infection have been used to identify the extrahepatic sites of HEV replication [10, 11] . HEV RNA was detected in samples of liver and bile but also in the cecum of naturally infected rabbits [10] . The virus loads in the liver, intestine, and cecum were not significantly different. Similarly, HEV RNA was detected in a wide variety of extrahepatic tissues of pigs inoculated intravenously with HEV. These included the kidneys, tonsils, salivary glands, stomach, spleen, lymph nodes, small intestine, and colon [11] . The HEV RNA concentrations in the faeces were at least 10 times higher than in the bile at similar times. Finally, HEV continued to replicate for longer in the liver, lymph nodes, small intestine, and colon tissues than in the other tissues tested. This indicates that the intestinal tract is a major site of HEV replication [11] .
The intestinal replication of HEV raises questions about the efficiency of antiviral drugs in this compartment. Little is known about the tissue distribution of ribavirin. Our patients with SVR and those who suffered a relapse were given similar ribavirin doses, and the plasma ribavirin concentrations in the 2 groups of patients were similar. Perhaps their intestinal ribavirin concentrations were different. A recent study that investigated the distributions of 2 nucleoside analogues, tenofovir and emtricitabin, in various tissues found wide variations in the intratissue concentrations between individual patients [12] . The drug concentrations in lymphatic tissues, ileum, and rectum were all low. Apparently suboptimal drug concentrations in reservoir tissues were associated with evidence of persistent HIV replication and the clinical consequence of chronic immune activation. Thus, it is quite possible that variations in the ribavirin concentration in the intestinal tract contribute to variations in the effectiveness of a given treatment, as has been found for antiretroviral drugs.
Our data suggest that testing for HEV RNA in both plasma and stool can help determine the duration of antiviral therapy. Those patients whose stools are still HEV RNA positive after 3 months of treatment should continue to be treated.
